Femasys (NASDAQ:FEMY – Get Free Report) and Co-Diagnostics (NASDAQ:CODX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.
Analyst Ratings
This is a summary of current ratings and recommmendations for Femasys and Co-Diagnostics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Femasys | 0 | 0 | 3 | 0 | 3.00 |
| Co-Diagnostics | 0 | 1 | 0 | 0 | 2.00 |
Femasys currently has a consensus target price of $11.33, suggesting a potential upside of 715.35%. Co-Diagnostics has a consensus target price of $2.50, suggesting a potential upside of 104.92%. Given Femasys’ stronger consensus rating and higher probable upside, equities analysts plainly believe Femasys is more favorable than Co-Diagnostics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Femasys | -1,329.10% | -105.47% | -80.50% |
| Co-Diagnostics | -518.69% | -35.37% | -32.58% |
Insider & Institutional Ownership
65.3% of Femasys shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 16.4% of Femasys shares are owned by insiders. Comparatively, 2.4% of Co-Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
Femasys has a beta of -2.76, suggesting that its stock price is 376% less volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of -0.65, suggesting that its stock price is 165% less volatile than the S&P 500.
Earnings and Valuation
This table compares Femasys and Co-Diagnostics’ gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Femasys | $1.07 million | 28.71 | -$14.25 million | ($0.92) | -1.51 |
| Co-Diagnostics | $6.81 million | 5.60 | -$35.33 million | ($1.21) | -1.01 |
Femasys has higher earnings, but lower revenue than Co-Diagnostics. Femasys is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
Femasys beats Co-Diagnostics on 8 of the 14 factors compared between the two stocks.
About Femasys
Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. In addition, the company provides non-surgical product technologies. It offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
About Co-Diagnostics
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.
